A deep mutational scanning platform to characterize the fitness landscape of anti-CRISPR proteins
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae1052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Tobias Stadelmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Synthetic Biology, Technical University of Darmstadt, Darmstadt 64287, Germany. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Escherichia coli, Gene Editing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Aventis Foundation, German Academic Scholarship Foundation.
Abstract (Originalsprache)
Deep mutational scanning is a powerful method for exploring the mutational fitness landscape of proteins. Its adaptation to anti-CRISPR proteins, which are natural CRISPR-Cas inhibitors and key players in the co-evolution of microbes and phages, facilitates their characterization and optimization. Here, we developed a robust anti-CRISPR deep mutational scanning pipeline in Escherichia coli that combines synthetic gene circuits based on CRISPR interference with flow cytometry coupled sequencing and mathematical modeling. Using this pipeline, we characterized comprehensive single point mutation libraries for AcrIIA4 and AcrIIA5, two potent inhibitors of CRISPR-Cas9. The resulting mutational fitness landscapes revealed considerable mutational tolerance for both Acrs, suggesting an intrinsic redundancy with respect to Cas9 inhibitory features, and – for AcrIIA5 – indicated mutations that boost Cas9 inhibition. Subsequent in vitro characterization suggested that the observed differences in inhibitory potency between mutant inhibitors were mostly due to changes in binding affinity rather than protein expression levels. Finally, to demonstrate that our pipeline can inform Acrs-based genome editing applications, we employed a selected subset of mutant inhibitors to increase CRISPR-Cas9 target specificity by modulating Cas9 activity. Taken together, our work establishes deep mutational scanning as a powerful method for anti-CRISPR protein characterization and optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Synthetic Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
- Department of Biology, Technical University of Darmstadt, Darmstadt 64287, Germany.
- Hochschule Offenburg, Faculty of Mechanical & Process Engineering, 77652 Offenburg, Germany.
- European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
- Institute of Pharmacy and Molecular Biotechnology (IPMB), Faculty of Engineering Sciences, Heidelberg University, Heidelberg 69120, Germany.
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, CH-1015, Switzerland.
ORCID-Profile: Dominik Niopek
Förderung
- German Research Foundation
- Aventis Foundation
- German Academic Scholarship Foundation
- Biltema Foundation
- National Center of Competence in Research Chemical Biology
- European Research Council
- Swiss National Science Foundation
Zitieren
APA
Stadelmann, T., Heid, D., Jendrusch, M., Mathony, J., Aschenbrenner, S., Rosset, S., Correia, B. E., & Niopek, D. (2024). A deep mutational scanning platform to characterize the fitness landscape of anti-CRISPR proteins. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae1052
Vancouver
Stadelmann T, Heid D, Jendrusch M, Mathony J, Aschenbrenner S, Rosset S, et al. A deep mutational scanning platform to characterize the fitness landscape of anti-CRISPR proteins. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae1052
BibTeX
@article{Stadelmann2024,
author = {Stadelmann, Tobias and Heid, Daniel and Jendrusch, Michael and Mathony, Jan and Aschenbrenner, Sabine and Rosset, Stéphane and Correia, Bruno E and Niopek, Dominik},
title = {A deep mutational scanning platform to characterize the fitness landscape of anti-CRISPR proteins},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae1052}
}
EUVIMED